IV IAS Sydney Video Library


		Dennis Altman, MA, Professor School of Sociology, Politics and Anthropology, Faculty of Humanities and Social Sciences, La Trobe University, President of the AIDS Society of Asia and the Pacific, IAS Governing Council Member, Melbourne, Victoria, Australia	Professor Altman advocates for strong national policy in AIDS prevention in every country worldwide. He provides a perspective of the past and is concerned that all countries provide prevention messaging that is the best that can be provided for each country with respect to and in consideration of their culture and traditions, while fighting for appropriate educational resources. He will provide his perspective for community advocacy to national governments that can and will change the statistical outcomes of this worldwide epidemic.

		Robert Bailey, PhD, MPH, Professor of Epidemiology at the School of Public Health, University of Illinois at Chicago and Research Associate, Field Museum, Chicago, Illinois, USA	Dr. Bailey reviews the randomized controlled trials uncovering the protective effect of circumcision against HIV transmission. The protective effect is impressive from a public health initiative, but how will we roll this out, to include other prevention methods and counseling. The statistical and therefore economic results are impressive, if only circumcision were to be aggressively implemented. He'll cover how accepted this procedure is in the resource poor communities.

		Ben Berkhout, PhD, Head, Department of Human Retrovirology, University of Amsterdam, Amsterdam, The Netherlands	Dr. Berkhout and his group have been uncovering evolution of the virus in moving through the process of natural selection and the phenominon of a host evolving a drug dependent virus among other phenomina. Although they are not doing this work for the prupose of vaccine development, he thinks it may indirectly contribute through the knowledge they learn from their work.

		Heiner C Bucher, MD, Professor, Doctor of Medicine, Kantonsspital Basel, Universitatskliniken, Basel, Switzerland	Dr. Bucher and his group give a more detailed look at the data, which more closely defines metabolic side effects and risk factors utilizing a new process which includes retrospectively and statistically reviewing the Swiss cohort study.

		Pedro Cahn, MD, PhD, President, International AIDS Society, Assistant Professor of Infectious Diseases, Buenos Aires University Medical School, Director, Fundacion Huesped, Buenos Aires, Argentina	As the Chair of the conference Dr. Cahn is well placed to take the reigns of the conference as a treatment activist himself, working to improve the prospect of access for every single person living with AIDS in every country in the world. His inspirational words and work has provided a framework for discussion and actions throughout his career and certainly now has an excellent platform on which to speak.

		Andrew Carr, MD, FRACP, FRCPA, Principal Investigator, The National Centre in HIV Epidemiology & Clinical Research, Associate Professor, St Vincent's Hospital Clinic School, University of New South Wales, Sydney, Australia	As a prominent researcher in the field of metabolic complications Dr. Carr describes the work that was presented at both the IAS, was well as, the Lipodystrophy & Adverse Drug Reactions meeting which immediatley preceeded the IAS meeting. He covered the possible drug contribution to lipoatrophy, relative risk of the protease inhibitors causing or contributing to diabetes, and the value of diet in preventing some metabolic complications in HIV. He summarizes many of the more interesting presentations from both conferences, many of which are of great interest to long-term survivors with AIDS.

		Stevie Clayton, OAM, CEO, AIDS Council of New South Wales, Sydney, Australia	Incredibly good social research in Australia has led Stevie Clayton and ACON to develop a strong and prolific program of peer evaluated prevention message reinforcement that works in the Sydney area. The program is constatly under review with specific messages being developed for each specific population and sexual sub-culture in the places where the "at risk" community congregates.

		Thomas J Coates, MD, Associate Director, UCLA AIDS Institute, Professore, Department of Medicine UCLA David Geffen School of Medicine, Los Angles, California, USA	Dr. Coates provides his perspective on where we are with pre-exposure prophylaxis as a prevention measure as well as the next steps for integration and by whom.

		David Cooper, MD, 4th IAS Conference on HIV Pathogenesis Treatment and Prevention, Director, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia	Dr. Cooper covers his support of the Start Trial, which will attempt to determine what immunologic point to begin treatment based upon the benefit that can be described in the realm of evidenced based medical research.

		Eric Daar, MD, Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of HIV Medicine, Harbor-UCLA Medical Center, Los Angeles, California, USA	Dr. Daar provides a look at the future of smartly integrating the new drugs currently becoming available and what will become available. He considers cross-resistance and drug sequencing as well as still leaving some options for the future. He’ll cover tough questions that have to be dealt with in managing advanced stage disease in patients with few options.

		Michael Dube, MD, Division of Infectious Diseases, Indiana University, Department of Medicine, Indianapolis, Indiana, USA	Dr. Dube covered his presentation regarding his research into endothelial function and the use of various protease inhibitors. His other study which also helped to answer the question of the association of reduced endothelial function and protease inhibitor use actually brought to light a separate relationship between the health of the blood vessels and limb fat in HIV positive individuals.

		Joseph J Eron, Jr, MD, Professor of Medicine in the Division of Infectious Diseases at the University of North Carolina Chapel Hill, School of Medicine	He speaks on the drugs recently approved or soon to be approved from the integrase, entry inhibitors and NNRTI classes of HIV drugs. From a general clinical perspective he presents the message of utilization of minimum two or better three new active drugs in a new regimen. He suggests some of the options to be considered based upon drug interaction and boosting requirements. While the message is more complex with the use of CCR5 entry inhibitors the benefit of another class seems to have potential for those who qualify as having appropriate genetic architecture to make use of the drug.

		Anthony Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), Bethesda, Maryland, USA	Dr. Fauci covers the importance of recognizing and addressing the worldwide need for treatment of TB and malaria, as well as, HIV/AIDS. He will cover the importance of the PEPFAR program reaching the global benchmarks and setting the example for other work which should follow. He brings the message to the IAS of how much more must be done.

		Nathan Ford, Medicines Sans Frontieres, Medical Advocacy Coordinator, Johannesburg, South Africa	Taped with Daniel O'Brien. Daniel and Nathan expressed their successes and challenges to current first line treatments, and the importance of making the best second line therapies delivered to the developing world and insuring that they are affordable and sustainable. they are looking at realistic implementation of brand medicines or generic medicines to the develoing world in an effifient standardized method.

		Kevin Robert Frost, Interim Executive Director, American Foundation for AIDS Research, New York City, New York, USA	Kevin will express his passion for and amfAR's commitment to draw attention to work that needs to be done around men who have sex with men in developing countries, tackling each country through facilitation of discussion between organizations and the governments of countries. He also covers the amfAR initiative "Treat Asia" which includes policy, treatment delivery capacity, education and training, and strengthening civil societies.

		Carl Grunfeld, MD, PhD, Professor of Medicine, Chief, Metabolism and Endocrine Sections, University of California Medical Center and Veterans Affairs Medical Center, San Francisco, California, USA	With the many studies covering clinical outcomes and racial differences, his groups study covered measured outcomes, to determine the effect of HIV treatment. In addition to this meeting he also covers a recent symposium organized by the American Heart Association and the Association of HIV Medicine Physicians which provided an insight regarding their perception of cardiovascular disease treatment concerns in HIV, and relative HIV treatment risks, as well as other non-HIV standard risks. He offers great council on smoking cessation.

		Richard Haubrich, MD, Professor of Medicine, Department of Medicine, Division of Infectious Diseases, University of California, San Diego, California, USA	Dr. Haubrich covers the use of recent trials that confirm the benefit of Drunavir as a treatment for experienced patients. He also offers his view as a clinician regarding the treatments to be reviewed as viable combinations for the treatment experienced. He anticipates the treatment naive data to be presented at the IAS and how to qualify naive patients readiness to engage in what may be life-long treatment.

		Robin Isaacs, MD, Executive Director of Clinical Research< Merch & Company, Inc., West Point, Pennsylvania, USA	Dr. Isaacs covers the background around the roll-out of their new integrase inhibitor. He'll cover some of the studies around the treatment experienced, treatment naive, expanded access and pediatric populations

		Quarraisha Abdool Karim, PhD, Associate Professor of Clinical Epidemiology, Columbia University Mailman School of Public Health, New York, New York, USA	As Associate Director of Center for the AIDS Program for Research in South Africa Doctor Karim advocated for scaling up TB and AIDS care in preperation for research to be conducted in the region, as well as, other integrated processes. She will edify the huge resource constraints and the enormous need for comprehensive access while currently serving and evaluating only very small numbers in these demonstration research projects funded by PEPFAR.

		Christine Katlama, MD, AIDS Clinical Research Unit, Groupe Hospitalier Pitie-Salpetriere, Paris, France	Dr. Katlama covers the resistance concerns around the Tibotec Phase III Duet Trials for TMC 125. She'll explain the importance of the use of multiple drugs to optimize the treatment benefit and some idea on where the treatment might best be used.

		Donald Kotler, MD, Chief, Division of Gastroenterology and Liver Disease, St. Luke's Roosevelt Hospital, New York City, New York, USA	He continues his long conversation with our community on the subject of body composition and related aging issues. He contributes the discussion that was had at the lipodystrophy meeting on belly fat and the consideration of other non-HIV related contributors. Drug related metabolic issues, as well as, family history and environmental issues will also be discussed.

		Daniel Kuritzkes, MD, Associate Professor of Medicine, Director of AIDS Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA	Dr. Kuritzkes offers his summary of the expectations of the new CCR5 antagonists and the test which evaluates the effectiveness of the two investigational CCR5 compounds. He offers his perspective about the risks and benefits of this new class of HIV treatments and some of the interesting, but certainly rare side effects.

		Katherine Leane, Director of NAPWA, Newtown, NSW, Australia	Katherine addresses the challenges of women living with HIV/AIDS. She expresses her view about choices of treatments, pregnancy, prevention and the role and importance of peer support for women and appropriate collaboration with industry, government and industry regulation.

		Michael Lederman, MD, Scott R. Inkley Professor of Medicine, Director of the Center for AIDS Research at Case Western Reserve University, Principal Investigator, University Hospital of Cleveland AIDS Clinical Trials Unit, Cleveland, Ohio, USA	Dr. Lederman will discuss the pathogenesis of HIV and how it makes people sick. He will discuss the early work that is still being confirmed as valid, as well as, some of the more recent work which is guiding our understanding in a slightly different direction. He uncovers the collaboration of researchers and scientists who meet periodically to bounce new ideas and theories relative to each of their own work which may be useful to each other.

		Jay A Levy, MD, Professor in Research, Medicine and Research Associate, Cancer Research Institute, UCSF, San Francisco, California, USA	Professor Levy has worked for years to better understand the innate immune system and the CD-9 antiviral factor (CAF) and it's robust and immediate activity once the host is infected. He discusses a bit more of what he has learned and the questions he still has about this area of work. Most important, he describes the possibilities for research into vaccines, trying to replicate this innate presumably natural protective activity.

		Craig McClure, Executive Director, International AIDS Society, Geneva Switzerland	Craig gives us a short tour of the IAS, its’ mission, conferences, and ongoing work. He reminds us of the many messages which are presented at the conference and how far we’ve come to address HIV but how far we must go to address every person living with HIV/AIDS in the World.

		John P Moore, PhD, Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Weill Medical College, Cornell University, New York City, New York, USA	One of the most perplexing concerns about AIDS denialism and it's impact on people living with AIDS and even some governmental policy. He also takes the opportunity to discuss the mechanism of resistance in CCR5 entry inhibitors and cross-resistance between current CCR5's research.

		Daniel O'Brien, MBBS FRACP, MSF Medical Advisor and Infectious Diseases Specialist, Geelong, Australia	Taped with Nathan Ford. Daniel and Nathan expressed their successes and challenges to current first line treatments, and the importance of making the best second line therapies delivered to the developing world and insuring that they are affordable and sustainable. they are looking at realistic implementation of brand medicines or generic medicines to the develoing world in an effifient standardized method.

		Nancy Padian, PhD, MPH, Executive Director of the University of California, San Francisco’s, Women’s Global Health Imperative, San Francisco, California, USA	Dr. Padian discussed with us her research on biomedical prevention strategies and her groups ability to determine better female control methods. She relates her positive experience with advocacy and science mixing it up at the IAS to learn from each other at conference sessions as well as in the halls of the conference. She would like to see more human behavioral research and research into the issues around stigma which must be addressed before a more comprehensive benefit.

		William C Powderly, MD, Head UCD School of Medicine and Medical Science, Professor of Medicine and Therapeutics, University College, Dublin, Ireland	Dr. Powderly will cover the new evidence from several studies about thymodine analogues and their contribution to lipoatrophy as opposed to what we originally presumed was protease inhibitors. He works in the field of bone disease and contributed to what was learned and confirmed what contributes to Osteopenia and Osteoporosis in HIV treatments, AIDS, as well as, age itself. He will speak to the accumulated or additive concerns of treatment over may years. Regardless of the added risks he makes the pitch for the simple preventative nutritional measures that can be taken to avert the consequences of Osteopenia.

		John Rossi, PhD, Professor and Chair of the Division of Molecular Biology, Dean of the Graduate School of Biological Sciences, City of Hope Beckman Research Institiute, Duarte, California, USA	Dr. Rossi is one of the first presenters of the RNAi targeting HIV, as the most powerful HIV inhibitory agent that has been experienced thus far, at least in the laboratory, back in 2001. So he has presented data on the successes he has had within a gene thrapy setting as a proof of concept in 2002. He will discuss the protocol that they are evaluating in a handful of patients with this gene contruct and in a vector that seems to work well. He will explain how this process works in as simple a manner as possible.

		Timothy Schacker, MD, Associate Professor, Department of Medicine, Institute for Molecular Virology, University of Minnesota Medical School, Minneapolis, Minnesota, USA	Timothy speaks on the importance of acute HIV infection to the human immune system and the location of , and damage to the CD-4's. He looks at this as it is important for scientists to understand this pathogenesis to be able to consider how to explore the prospect of true and more complete immune reconstitution as well as even why and when to strart therapy.

		Annette H Sohn, MD, Assistant Professor, Division of Pediatric Infectious Diseases, Institute for Global Health, University of California, San Francisco, USA	The Treat Asia Pediatric Network is building capacity for conducting more research and education training in the Pacific Region with stakeholders in the region. She’ll address the priority setting that they have accomplished and describe the database which was established to conduct surveillance in epidemiology to look at outcomes of the treatment of children in the regional clinics and hospitals. She will discuss how this effort will be useful to other countries beyond Viet Nam.

		Sharon Walmsley, MSc, MD, Professor of Medicine, Division of Infectious Diseases, University of Toronto, Toronto Hospital, Toronto, Ontario, Canada	Dr. Walmsley presents her concerns about the need to know the optional starting point for people living with HIV and the how and when to encourage patients to start. She'll also convey some of the issues around what to start with, whether NNRTI's or PI or other possibilities, as well as, the three drug combo's to get to undetectable for the treatment experienced patients.

		Mitchel Warren, Executive Director, AIDS Vaccine Advocacy Coalition, New York, New York, USA	Mitchell discusses the large vaccine trials and expectations of the results of those trials regarding cell mediated immunity. He strongly advocates for the comprehensive prevention/research consortia all working for the common good and with a goal to blunt if not defeat the virus that causes AIDS. This interview provides an in depth perspective of the importance of AIDS advocacy for the long-term.

		Kevin Yarasheski, PhD, Associate Professor of Medicine, Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA	Dr. Yarasheski speaks about his data on Pioglitazone (Actos) and exercise synergistically working to improve body composition. Actos is currently approved for diabetes and insulin resistance and type II diabetics. He'll review the results with sub-Q fat, T-cells, fluid retention, blood cells, liver enzymes, and blood fat. He'll also speak to his work with Yoga as a possibility of it improving chloresterol, and sugar levels. His main focus in research is on how to live longer and better with HIV disease.

		Debrework Zewdie, PhD, Director, Global HIV/AIDS Program, World Bank, Washington, District of Columiba, USA	Doctor Zewdie will discuss the most cost effective way to care for people who live with the life-threatening disease with the broad acknowledgement of HIV treatment being not only possible but enormously effective and essential from the standpoint of humanity, but also to sustain the workforce of countries most hard hit by HIV, Malaria, and TB.